{"id":"NCT02320721","sponsor":"Sanofi","briefTitle":"Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications","officialTitle":"A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on Antidiabetic Regimens Either Including no Insulin, or With Basal Insulin as Their Only Insulin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01","primaryCompletion":"2016-05","completion":"2016-05","firstPosted":"2014-12-19","resultsPosted":"2017-07-11","lastUpdate":"2020-04-21"},"enrollment":1014,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Insulin Glargine (HOE901 - U300)","otherNames":["Toujeo®"]},{"type":"DRUG","name":"Insulin Glargine (HOE901 - U100)","otherNames":["Lantus®"]},{"type":"DRUG","name":"Background therapy","otherNames":[]}],"arms":[{"label":"HOE901-U300","type":"EXPERIMENTAL"},{"label":"Lantus","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate the non-inferiority of H0E901-U300 to Lantus, in change of glycated hemoglobin A1c (HbA1c).\n\nSecondary Objectives:\n\nTo demonstrate the superiority of H0E901-U300 in comparison with Lantus in:\n\n* Percentage of participants with at least one severe and/or confirmed (by plasma glucose ≤70mg/dL \\[3.9mmol/L\\]) hypoglycemia event from 22:00 to 08:59 next morning\n* Percentage of participants with at least one nocturnal (from 00:00-05:59) severe and/or confirmed (≤70mg/dL \\[3.9mmol/L\\]) hypoglycemia event\n* Percentage of participants with at least one severe and/or confirmed (by plasma glucose ≤70mg/dL \\[3.9mmol/L\\]) hypoglycemia event occurring at any time of day\n* HbA1c change","primaryOutcome":{"measure":"Change in HbA1c From Baseline to Week 26","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"HOE901-U300","deltaMin":-0.89,"sd":0.038},{"arm":"Lantus","deltaMin":-0.91,"sd":0.042}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":162,"countries":["United States","Argentina","Australia","Canada","Colombia","France","Germany","Hungary","Italy","Japan","Mexico","Peru","Poland","Romania","South Korea","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["29895556"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":41,"n":508},"commonTop":["Nasopharyngitis","Upper respiratory tract infection"]}}